CPT
Dortmund, Germany
CPT
Dortmund, Germany

Time filter

Source Type

News Article | May 2, 2017
Site: www.marketwired.com

Release of Comprehensive Page-Level Traffic dataset provides industry-leading granularity for fighting back against ad impressions from bots and undesirable traffic GREENWOOD VILLAGE, CO--(Marketwired - May 2, 2017) - zvelo, the leading provider of categorization and malicious detection data for web pages, devices and traffic, today announced the immediate availability of the Comprehensive Page-Level Traffic (CPT) dataset. CPT allows advertisers, ad-tech platforms, and suppliers to get thorough visibility into the quality (or lack thereof) of ad impressions, down to a specific web page. This level of detail exceeds higher-level domain-based insight, enabling companies to be much smarter and more accurate with how they budget and execute their digital campaigns. While domain data might provide a cursory overview of a website's traffic trends, the deep-dive granularity of zvelo's page-level dataset offers specificity not yet seen in the industry. zvelo customers using CPT will place a lightweight JavaScript tag (called the zTag) across all or a subset of targeted web pages or ad creatives. Customers then gain comprehensive classification data and insight into the validity of that specific page's web traffic. With this knowledge, they are armed with data that gives them many options: they can work with suppliers to clean up specific traffic generation efforts, choose to move ad spend away from undesirable pages or domains, or enforce traffic cleanliness standards. The CPT dataset is also designed to easily integrate into the reporting tool of the customer's choosing. "Digital ad fraud continues to eat away too much of digital advertising budgets," said Cordell BaanHofman, Vice President of Business Development, zvelo. "As problems with non-human and low-quality traffic continue to rise, it is increasingly critical that businesses have accurate, up-to-date data guiding their decisions about where and how to reach desired audiences. zvelo's Comprehensive Page-Level Traffic dataset now provides the deepest level of web traffic quality information available in the market." CPT is being released following the successful launch of zvelo's free bot detection service, also an industry first. Digital marketing businesses continue to deploy this service to quickly determine which website impressions are invalid, low quality, or non-human. CPT's page-level knowledge can work as a more-actionable complement to businesses already using zvelo's free bot detection capabilities. "As an early user of zvelo's CPT dataset, we've seen firsthand what this service is capable of," said Clint Ethington, CEO, Genius Monkey. "CPT has provided our programmatic advertising platform with a critical layer of insight at the page level. It has enabled us to stop 130% more ad fraud than the industry-best averages, based on our recently completed 10-month study. zvelo has been extremely responsive to our needs every step of the way, and we look forward to continuing to address brand safety and fraud in the ad tech industry using zvelo's solutions." Some advertisers will choose to pair CPT with zvelo's Invalid Traffic (IVT) dataset. IVT delivers a continuously updated stream of IPs detected as bot and non-human traffic. This allows customers the ability to block inventory originating at the bidder level. zvelo's CPT dataset is priced through a monthly flat fee and variable CPM, based on usage. As a leading provider of content categorization and malicious detection data for webpages, devices and traffic, zvelo is the trusted partner for the market's preeminent ad tech, network security, and mobile service provider/subscriber analytics vendors. zvelo solves a diverse range of client business needs including providing the foundational datasets for web filtering, parental controls, brand safety, contextual targeting, subscriber analytics, and ad fraud prevention. zvelo, headquartered just outside of Denver, is committed to providing the market's highest quality data products and best responsiveness. The company has additional offices in the Philippines and Florida. To receive more information about this topic, or schedule an interview, email: pr@zvelo.com.


Chicago, IL (May 6, 2017) -- Genotyping of patients with advanced cirrhosis from hepatitis C virus could help health-care professionals predict the likelihood of improvement after successful hepatitis C treatment, thus minimizing the need for liver transplants. This study was presented at Digestive Disease Week® (DDW) 2017, the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. "Our findings further the move toward precision medicine, because we can potentially use a person's genetic makeup to identify individuals who can benefit most from hepatitis C treatment, even at a very late stage in the progression of their liver disease," said Winston Dunn, MD, the study's lead author and associate professor at the University of Kansas Medical Center. Most patients with hepatitis C virus (HCV) can be cured by direct-acting antiviral agents, but some of those with the more serious decompensated cirrhosis, or liver damage, fail to improve or experience further deterioration even after treatment. Features of decompensated cirrhosis include confusion, swelling and jaundice. Dr. Dunn and his team focused on the Rs738409 single nucleotide polymorphism (RSP), which is a variation in a single base pair of DNA in the PNPLA3 gene; patients possess one of three genotypes -- CC, CG, or GG. The PNPLA3 gene is the most important genetic risk factor for both alcoholic liver disease and nonalcoholic fatty liver disease. The team followed 32 patients with decompensated cirrhosis at the University of Kansas Medical Center who had initially achieved sustained virologic response (SVR). They had become essentially virus-free, using interferon-free direct-acting antiviral medications, such as sofosbuvir/ledipasvir and sofosbuvir/simeprevir. Twelve to 48 weeks after SVR, researchers tracked changes in two measures that assess the severity of chronic liver disease, the Model for End-Stage Liver Disease (MELD) and the Child-Pugh (CPT) scores. Following the antiviral treatment, researchers found that five of the 16 patients with the CG or GG genotypes experienced worsened MELD or CPT scores. In comparison, only one of the patients with the CC genotype worsened in either CPT or MELD scores. "These findings suggest screening for the Rs738409 CG and GG genotypes in hepatitis C patients with decompensated cirrhosis can help to identify individuals who are less likely to recover after achieving a 'cure' of their hepatitis C," added Dr. Dunn. "Until now, we have not had a method to distinguish between the individuals who would recover given equal severity in baseline disease." As next steps, Dr. Dunn noted that his team will examine the underlying mechanisms that may explain why the presence of these genotypes lead to worsened health outcomes. They'll study how fatty liver and insulin resistance impact clinical recovery after treatment with direct-acting antiviral medications, and if these findings correspond to that of the genetic marker for fatty liver (Rs738409). Financial support for this study was provided by the Frontiers Pilot and Collaborative Studies Funding Program. Dr. Winston Dunn will present data from the study, "Rs738409 SNP of PNPLA3 Gene Predicts Clinical Recovery in Patients with Decompensated Hepatitis C Cirrhosis After Attaining Sustained Virological Response" abstract Sa1535, on Saturday, May 7, at 9:30 a.m. CT, in South Hall of McCormick Place. For more information about featured studies, as well as a schedule of availability for featured researchers, please visit http://www. . Digestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy, and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy (ASGE), and the Society for Surgery of the Alimentary Tract (SSAT), DDW takes place May 6-9, 2017, at McCormick Place, Chicago. The meeting showcases more than 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at http://www. .


Dublin, April 19, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Mild Hybrid 48V Vehicles 2016-2031 - Market Forecasts and Technology Roadmaps for Cars, Trucks and Other Vehicles" report to their offering. This unique report is presented in very detailed wide format slides. Only a global up-to-date view makes sense in this fast-moving subject. Therefore the multilingual PhD level analysts have travelled intensively in 2015 and 2016 to report the latest research, conferences and expert opinions and to analyse how the markets and technologies will move over the coming 15 years. Original tables and infographics pull together the analysis. The comprehensive Executive Summary and Conclusions embraces market forecasts 2016-2031 for 48V systems in cars and for the different types of electric car which compete with 48V systems to replace conventional cars. For clarity, many infographics are presented. This is analysis by experts not simply a consolidation of information out there. The new, original figures for the addressable market for 48V cars is plotted alongside the figures likely to be achieved for this period. The 48V technology roadmap is put in context by overall electric vehicle technology trends in infographics. Based on Volkswagen methodology, the four generations of 48V system are scoped in time this extra information giving a wider opportunity than that normally addressed. For example, many forms of multiple energy harvesting and recuperation will be enabled. There is then a Technology Analysis which includes a look at the synergy with 48V pure electric powertrains. The widening range of 48V parts being added to the basic 48V systems is investigated as they progress towards 48V alone. The relevance to small vs large cars and premium vs mainstream cars is clarified by year then the progress with the different building blocks is examined in depth. In particular, the reversible torque assisting motor generator is examined, comparing the different options being pursued such as permanent magnet vs switched reluctance synchronous and the option of asynchronous. Throughout, the views and forecasts of leading vehicle manufacturers and their Tier One suppliers is surfaced as well as those of the innovative small companies. The component analysis is thorough, embracing, for example, lithium-ion vs Advanced Lead Acid batteries and what comes after them. Latest progress with the most significant collaborative programs is revealed and the proliferation of energy harvesting and recuperation options is studied in detail. Key Topics Covered: 1. EXECUTIVE SUMMARY AND CONCLUSIONS 1.1. Why and What 1.2. Carbon dioxide reduction 1.3. First generation 1.4. Powertrain winners and losers 2016-2026 1.5. The technological heart 1.6. Company positioning: best solutions for market needs 2016-2030 1.7. Hype curve for car powertrains in 2016 1.8. When will it be entirely 48V? 1.9. Market Forecasts 1.9.1. 48V cars - forecasts, end game 2016-2031 1.9.2. Powertrain forecasts 2016-2031 1.10. Technology Roadmaps 1.10.1. Four generations 2015-2031 1.10.2. Other roadmaps putting 48V in context 1.10.3. Technology timeline 2016-2026 2. TECHNOLOGY ANALYSIS 2.1. Types of conventional and electric vehicle - two 48V opportunities 2.2. Synergy between 48V mild hybrids and 48V pure electric powertrains? 2.2.1. Voltage trends for pure electric vehicles: 48V opportunity 2.2.2. Voltage choices by powertrain 2.3. Heart of a 48V mild hybrid: popular starting point 2.4. The widening choice of 48v components 2.5. Engine downsizing and boosting 2.6. Safety 2.7. Suitability of 48V by car size over time 2017-2027 and 2031 2.8. Progress with the 48V building blocks 2.9. Future of 48v rotating machine technology 2.9.1. Evolution from stop-start to multifunctional rotating machines 2.9.2. Operating modes, design priorities 2.9.3. View of Continental: BAS 2.9.4. Construction options for reversible machines 2.10. Future of the DC DC converters 2.11. Projects comparing 48V options: examples 2.11.1. Jaguar Land-Rover and Partners UK 2.11.2. LC SuperHybrid UK 2.11.3. Volvo Sweden, China 2.11.4. Hyundai Korea 2.11.5. US Department of Energy Civic Ultrabattery Road Test 2.11.6. ARPA-E Award USA 2.11.7. ADEPT: one of the most significant 48V development projects worldwide 2.11.8. Healthy disagreement about system functions and components 2.11.9. Schaeffler, Ford, Continental 2.12. Batteries for 48V mild hybrid 2.12.1. Overview 2.12.2. Powertrain battery choices 2.13. 48V superchargers 2.14. Flywheel KERS 2.15. Future 48V motor controllers 2.16. Energy harvesting including regeneration 2.16.1. Vehicle fuel wastage by origin - target of regeneration 2.16.2. Energy harvesting choice for vehicles 3. CONFERENCE REPORT 3.1. Lessons from 48V event Dusseldorf Germany 24-26 Nov 2015 4. EXAMPLES OF INTERVIEWS 2015-2016 4.1. Ongoing interviews in USA, East Asia, Europe 4.1.1. Accepted trend 4.1.2. Window of opportunity for 48V MH cars 4.1.3. 48V PbA batteries? 4.1.4. When will 12V batteries be gone? 4.1.5. 48V MH buses and off road 4.2. ALABC/ILA London 12 Jan 2016 4.3. Visit to Controlled Power Technologies CPT Ltd UK 18 January 2016 4.4. MAHLE APPENDIX: FROM SYSTEM TO PRODUCT TT ELECTRONICS/AB MIKROELEKTRONIK GMBH For more information about this report visit http://www.researchandmarkets.com/research/mzjnlh/mild_hybrid_48v


Dublin, April 19, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Mild Hybrid 48V Vehicles 2016-2031 - Market Forecasts and Technology Roadmaps for Cars, Trucks and Other Vehicles" report to their offering. This unique report is presented in very detailed wide format slides. Only a global up-to-date view makes sense in this fast-moving subject. Therefore the multilingual PhD level analysts have travelled intensively in 2015 and 2016 to report the latest research, conferences and expert opinions and to analyse how the markets and technologies will move over the coming 15 years. Original tables and infographics pull together the analysis. The comprehensive Executive Summary and Conclusions embraces market forecasts 2016-2031 for 48V systems in cars and for the different types of electric car which compete with 48V systems to replace conventional cars. For clarity, many infographics are presented. This is analysis by experts not simply a consolidation of information out there. The new, original figures for the addressable market for 48V cars is plotted alongside the figures likely to be achieved for this period. The 48V technology roadmap is put in context by overall electric vehicle technology trends in infographics. Based on Volkswagen methodology, the four generations of 48V system are scoped in time this extra information giving a wider opportunity than that normally addressed. For example, many forms of multiple energy harvesting and recuperation will be enabled. There is then a Technology Analysis which includes a look at the synergy with 48V pure electric powertrains. The widening range of 48V parts being added to the basic 48V systems is investigated as they progress towards 48V alone. The relevance to small vs large cars and premium vs mainstream cars is clarified by year then the progress with the different building blocks is examined in depth. In particular, the reversible torque assisting motor generator is examined, comparing the different options being pursued such as permanent magnet vs switched reluctance synchronous and the option of asynchronous. Throughout, the views and forecasts of leading vehicle manufacturers and their Tier One suppliers is surfaced as well as those of the innovative small companies. The component analysis is thorough, embracing, for example, lithium-ion vs Advanced Lead Acid batteries and what comes after them. Latest progress with the most significant collaborative programs is revealed and the proliferation of energy harvesting and recuperation options is studied in detail. Key Topics Covered: 1. EXECUTIVE SUMMARY AND CONCLUSIONS 1.1. Why and What 1.2. Carbon dioxide reduction 1.3. First generation 1.4. Powertrain winners and losers 2016-2026 1.5. The technological heart 1.6. Company positioning: best solutions for market needs 2016-2030 1.7. Hype curve for car powertrains in 2016 1.8. When will it be entirely 48V? 1.9. Market Forecasts 1.9.1. 48V cars - forecasts, end game 2016-2031 1.9.2. Powertrain forecasts 2016-2031 1.10. Technology Roadmaps 1.10.1. Four generations 2015-2031 1.10.2. Other roadmaps putting 48V in context 1.10.3. Technology timeline 2016-2026 2. TECHNOLOGY ANALYSIS 2.1. Types of conventional and electric vehicle - two 48V opportunities 2.2. Synergy between 48V mild hybrids and 48V pure electric powertrains? 2.2.1. Voltage trends for pure electric vehicles: 48V opportunity 2.2.2. Voltage choices by powertrain 2.3. Heart of a 48V mild hybrid: popular starting point 2.4. The widening choice of 48v components 2.5. Engine downsizing and boosting 2.6. Safety 2.7. Suitability of 48V by car size over time 2017-2027 and 2031 2.8. Progress with the 48V building blocks 2.9. Future of 48v rotating machine technology 2.9.1. Evolution from stop-start to multifunctional rotating machines 2.9.2. Operating modes, design priorities 2.9.3. View of Continental: BAS 2.9.4. Construction options for reversible machines 2.10. Future of the DC DC converters 2.11. Projects comparing 48V options: examples 2.11.1. Jaguar Land-Rover and Partners UK 2.11.2. LC SuperHybrid UK 2.11.3. Volvo Sweden, China 2.11.4. Hyundai Korea 2.11.5. US Department of Energy Civic Ultrabattery Road Test 2.11.6. ARPA-E Award USA 2.11.7. ADEPT: one of the most significant 48V development projects worldwide 2.11.8. Healthy disagreement about system functions and components 2.11.9. Schaeffler, Ford, Continental 2.12. Batteries for 48V mild hybrid 2.12.1. Overview 2.12.2. Powertrain battery choices 2.13. 48V superchargers 2.14. Flywheel KERS 2.15. Future 48V motor controllers 2.16. Energy harvesting including regeneration 2.16.1. Vehicle fuel wastage by origin - target of regeneration 2.16.2. Energy harvesting choice for vehicles 3. CONFERENCE REPORT 3.1. Lessons from 48V event Dusseldorf Germany 24-26 Nov 2015 4. EXAMPLES OF INTERVIEWS 2015-2016 4.1. Ongoing interviews in USA, East Asia, Europe 4.1.1. Accepted trend 4.1.2. Window of opportunity for 48V MH cars 4.1.3. 48V PbA batteries? 4.1.4. When will 12V batteries be gone? 4.1.5. 48V MH buses and off road 4.2. ALABC/ILA London 12 Jan 2016 4.3. Visit to Controlled Power Technologies CPT Ltd UK 18 January 2016 4.4. MAHLE APPENDIX: FROM SYSTEM TO PRODUCT TT ELECTRONICS/AB MIKROELEKTRONIK GMBH For more information about this report visit http://www.researchandmarkets.com/research/mzjnlh/mild_hybrid_48v


drchrono demonstrates new features at the 2017 American Congress of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting in San Diego, CA MOUNTAIN VIEW, CA--(Marketwired - May 5, 2017) -  drchrono Inc., the provider of the Electronic Health Record (EHR), practice management, medical billing, revenue cycle management (RCM), and healthcare API platform on iPad, iPhone and web, today announced it will showcase new Flow Sheets and medical forms specialized for OB/GYN physicians and practices at the 2017 American Congress of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting taking place May 6-9, 2017 in San Diego, CA. Using Prenatal Flow Sheet in drchrono, providers and their staff can easily enter patients' medical records from each visit and visualize pregnancy progress across multiple visits in one glance on an iPhone, iPad or via the web. The drchrono Flow Sheet can also be further customized to meet providers' specific needs. Flow Sheet and other medical forms in drchrono then can be compiled and sent to Labor & Delivery, and other providers or the provider's billing team by using drchrono's direct messaging integration with local hospital EHRs or integrated e-Fax. In addition, drchrono built and added five essential OB/GYN medical forms to its medical form library for immediate use. These forms include: Antepartum Record, Obstetric Medical History, Postpartum Care Plan, Prenatal Visits and Progress Notes. All OB/GYN providers using drchrono EHR have free access to the forms at https://app.drchrono.com/ehr-emr/medical-form-templates/1937806/prenatal-visits. "drchrono's EHR is very easy for doctors to make great notes and has a wide breadth of functionality including customized medical forms, patient portal, e-faxing, direct messaging, automated electronic reminders, diagramming and photos in charts. It's also great that drchrono continually improves their system," said Dr. Eesha Bhattacharyya, M.D., Ko'olau Women's Healthcare Oahu, HI. "Flow Sheet will give us better flexibility and efficiency in tracking vital patient information. I am looking forward to the benefits it will provide to my patients and practice." "OB/GYNs are requiring more powerful clinical tools that will help them improve patient engagement and track vital statistics," said Daniel Kivatinos, COO and Co-founder, drchrono. "We work closely with our physician customers to gather feedback on what's essential and added new Flow Sheets and prebuilt medical forms to provide OB/GYNs sophistication and efficiency in tracking and documenting patient data." OB/GYN practices can also maximize revenue collection with drchrono's medical billing software or full service Revenue Cycle Management (RCM). drchrono EHR automatically populates any combination of OB/GYN specific codes (ICD10, CPT and E&M codes) into EHR medical forms to simplify the billing process. drchrono's certified billing coders are fluent with hundreds of new OB/GYN codes and well versed with OB/GYN medical billing practices optimizing clean claim rates, collections and payments. drchrono is a sponsor at the 2017 American Congress of Obstetricians and Gynecologists (OCOG) Annual Clinical and Scientific Meeting and will be located at booth #655. For more details on the event or to register to attend, visit http://annualmeeting.acog.org/. About drchrono drchrono creates the best electronic health record (EHR), practice management, and revenue cycle management experience for physicians and patients; the drchrono platform was built for iPad, iPhone, Apple Watch and the web. The drchrono platform includes customizable medical forms, e-prescribing, real-time patient eligibility checks, patient portal, medical billing and more. The platform also provides a multitude of healthcare apps that the practices can leverage and a medical API for healthcare app developers. The company is scheduling over 1 million appointments per month. drchrono is ranked by Inc. 500 as one of the fastest growing private companies in America, and the platform was voted the #1 mobile EHR 4 years in a row by Black Book Rankings. For more information about drchrono, visit www.drchrono.com


OMER, ISRAEL--(Marketwired - May 4, 2017) - Medigus Ltd. ( : MDGS) ( : MDGS), a medical device company developing minimally invasive endosurgical tools and a leader in direct visualization technology, today announced that three poster presentations featuring new data on the MUSE™ System will be presented at the upcoming Digestive Disease Week® (DDW), being held in Chicago from May 6-9, 2017. "We are pleased to have new clinical findings to share at DDW this year, including the interim results from a multi-center trial," said Chris Rowland, Chief Executive Officer of Medigus. "The data focuses on the outcomes of using MUSE, a minimally invasive solution for GERD. Our system can help reduce the unmet treatment need for patients who fall within the gap between drug therapy and invasive surgical procedures." The MUSE system is a single-use flexible transoral stapler that merges the latest advancements in microvisual, ultrasonic and surgical stapling. The device comes equipped with an ultrasonic sight and range finder and a micro ScoutCam™ CMOS camera, which enables a single physician to perform an incisionless transoral fundoplication -- the procedure intended to treat the anatomical cause of gastroesophageal reflux disease (GERD). Institutions: 1. Boarland-Groover Clinic, Jacksonville, FL, United States. 2. Policlinico A. Gemelli, Rome, Italy. 3. Evangelisches Krankenhaus, Dusseldorf, Germany. 4. NYU Langone Medical Center, New York, NY, United States. 5. Horst Schmidt Kliniken, Ludwigsburg, Germany. 6. Winthrop Hospital, Mineola, NY, United States. 7. Mayo Clinic, Rochester, MN, United States. 8. Kliniken Ludwigsburg, Ludwigsburg, Germany. 9. Indiana University Indianapolis, Indiana, IN, United States. 10. Univ. of Texas Health, Houston, TX, United States. 11. Univ. of CA Irvine, Orange, CA, United States. 12. Ospedale San Raffaele, Milan, Italy. To learn more about MUSE, visit: www.medigus.com About Medigus Medigus is a medical device company specializing in developing minimally invasive endosurgical tools and highly innovative imaging solutions. They are the pioneer developer of the MUSE™ system, an FDA cleared and CE marked endoscopic device to perform Transoral Fundoplication (TF) for the treatment of GERD (gastroesophageal reflux disease), one of the most common chronic conditions in the world. In 2016, the CMS established the Category I CPT® Code of 43210 for TF procedures, such as the ones performed with MUSE, which establishes reimbursement values for physicians and hospitals. MUSE is gaining adoption in key markets around the world - it is available in world-leading healthcare institutions in the U.S., Europe and Israel. Medigus is also in the process of obtaining regulatory clearance in China. Medigus is traded on the Nasdaq Capital Market and the TASE (Tel-Aviv Stock Exchange). To learn more about the company's advanced technology, please visit www.medigus.com or www.RefluxHelp.com. This press release may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions and expectations of the company's management and its knowledge of the relevant market. The company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words. These forward-looking statements represent Medigus' expectations or beliefs concerning future events, and it is possible that the results described in this news release will not be achieved. By their nature, Forward-Looking Statements involve known and unknown risks, uncertainties and other factors which may cause future results of the company's activity to differ significantly from the content and implications of such statements. Other risk factors affecting the company are discussed in detail in the Company's filings with the Securities and Exchange Commission. Forward-Looking Statements are pertinent only as of the date on which they are made, and the company undertakes no obligation to update or revise any Forward-Looking Statements, whether as a result of new information, future developments or otherwise. Neither the company nor its shareholders, officers and employees, shall be liable for any action and the results of any action taken by any person based on the information contained herein, including without limitation the purchase or sale of company securities. Nothing in this press release should be deemed to be medical or other advice of any kind.


News Article | May 8, 2017
Site: www.prnewswire.com

"It gives me great pride to announce that the iFuse ProcedureTM is considered a proven treatment by the United States Defense Health Agency and can now be appropriately offered to active and retired military personnel and their family members," said Michael Mydra, SI-BONE's Vice President, Health Outcomes & Reimbursement.  "SI-BONE is pleased to be able to help all the brave men and women in our armed forces for their service to our country." "Earlier this year, we met with Colonel Stephen C. Phillips, DO, MPH and his staff at the Defense Health Agency in Washington, D.C. and reviewed the extensive published clinical evidence for the iFuse Implant.  Following that meeting, the TRICARE policy team determined that coverage for MIS sacroiliac joint fusion was appropriate and warranted," said Tony Recupero, Chief Commercial Officer at SI-BONE.  "We are now fully engaged with physicians at military facilities across the country to assist them in providing iFuse to appropriately diagnosed military personnel." The SI joint has been attributed as a source of pain in 15-30 percent of patients with chronic low back pain1-4, and in up to 43 percent of patients with new onset or persistent low back pain after lumbar fusion.5 Like all other major joints, the SI joint can be injured or degenerate, which can cause debilitating pain in the lower back, buttocks and legs.  Simple movements such as standing up, sitting down, stepping up or down, bending and lifting, walking, or even sleeping or sitting on the affected side can provoke a symptomatic SI joint. SI joint dysfunction is often misdiagnosed and the resulting pain can be misattributed to other causes.  Not all healthcare providers evaluate the SI joint and many patients do not know to ask about it. While not commonly diagnosed, SI joint disorders can be identified when a patient points to their source of pain directly over the posterior superior iliac spine (PSIS) known as the Fortin Finger Sign, combined with a number of positive provocative maneuvers to stress the SI joint and elicit the pain, followed by image-guided diagnostic injections. The other major joints in the human body, such as knees, hips, ankles and shoulders, have specialized device-based surgical solutions.  The SI joint is the largest and the last of eight major joints in the human body to have a proven surgical solution.  The iFuse ImplantTM was designed specifically to withstand the extreme forces resulting from load-bearing and the unique rotational and translational motion of the SI joint referred to as nutation, and is supported by more than 50 peer reviewed publications including two level 1 randomized controlled trials. About SI-BONE, Inc. SI-BONE, Inc. (San Jose, California) is a leading medical device company that has developed the iFuse Implant System, a proprietary minimally invasive surgical implant system to fuse the sacroiliac joint to treat common disorders of the joint that can cause lower back pain.  Patients with sacroiliac joint dysfunction experience pain that can be debilitating.  SI-BONE believes that the sacroiliac joint is the last of the eight major joints in the human body to have a proven surgical treatment and that the iFuse Implant is the only device for treatment of SI joint dysfunction supported by significant published clinical evidence, including level 1 trials, showing safety and durable effectiveness, including providing lasting pain relief. The iFuse Implant System is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis.  This includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than 6 months.  There are potential risks associated with the iFuse Implant System.  It may not be appropriate for all patients and all patients may not benefit.  For information about the risks, visit: www.si-bone.com/risks CPT copyright 2017 America Medical Association.  All rights reserved.  CPT is a registered trademark of the American Medical Association. The AMA assumes no liability for data contained or not contained herein. SI-BONE and iFuse Implant System are registered trademarks of SI-BONE, Inc. ©2017 SI-BONE, Inc. All Rights Reserved. 9876.050817 To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/si-bone-inc-announces-us-militarys-tricare-now-covers-mis-si-joint-fusion-300452667.html


News Article | March 8, 2017
Site: globenewswire.com

NASHUA, N.H., March 08, 2017 (GLOBE NEWSWIRE) -- iCAD, Inc. (Nasdaq:ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today reported financial results for the three and twelve months ended December 31, 2016. “Our fourth quarter revenue grew 15% sequentially compared to the third quarter of 2016, reflecting improved performance in our cancer therapy business,” said Ken Ferry, Chief Executive Officer.  “This included a stronger quarter for IORT system and balloon applicator sales, as result of greater sales activity, and increased procedure volume in both the U.S. and international markets.  We also had our strongest quarter of the year adding new customers in our skin electronic brachytherapy business.  Our cancer detection team continues to make good progress with the development of software tools that enhance the workflow and interpretation of 3D tomosynthesis breast exams.  We expect these tools to be a major growth opportunity for the Company over time.  Currently, these products are available in certain international markets and are pending FDA clearance in the United States.” Mr. Ferry added, “We remain confident in the longer term outlook for our business.  In the fourth quarter we made additional key investments in support of our goal of obtaining a CPT 1 reimbursement code for skin electronic brachytherapy, added sales personnel to support future growth in the skin therapy and cancer detection software markets, and had a robust presence at the two most important medical meetings that we attend, ASTRO and RSNA.  Also, in January 2017, we strengthened our balance sheet with the sale of our MRI CAD business for $3.2 million.” Revenue:  Total revenue for the fourth quarter of 2016 decreased 9% to $6.9 million from $7.6 million in the fourth quarter of 2015, reflecting a 15% increase in product revenue and a 21% decrease in service revenue.  The decrease in the Company’s revenue in the fourth quarter of 2016 was primarily driven by the comparable decline of therapy service revenue associated with the treatment of non-melanoma skin cancer in the United States.  On a sequential quarter basis, total revenue for the fourth quarter of 2016 increased 15% from $6.0 million in the third quarter of 2016.  Service revenue for the fourth quarter of 2016 was approximately 57% of total revenues compared to approximately 65% of total revenues in the fourth quarter of 2015. Cancer detection revenue for the fourth quarter of 2016 decreased by 3%, which includes digital mammography, breast density, MRI and CT CAD platforms, as well as the associated service revenue.  Therapy revenue decreased by 17%, which includes Xoft® Axxent® Electronic Brachytherapy System® product sales, as well as the associated service revenue. Gross Profit:  Gross profit for the fourth quarter of 2016 decreased to $4.5 million, or 65% of revenue, from $5.3 million, or 70% of revenue, for the fourth quarter of 2015. Operating Expenses:  Total operating expenses for the fourth quarter of 2016 increased to $7.8 million from $7.6 million for the fourth quarter of 2015. The year-over-year increase reflects investments in strategic growth drivers, partially offset by the Company’s cost reduction initiatives which were implemented in 2015. GAAP Net Loss:  Net loss for the fourth quarter of 2016 was $(3.3) million, or $(0.20) per share, compared with net loss of $(2.4) million, or $(0.15) per share, for the fourth quarter of 2015. Non-GAAP Adjusted EBITDA:  Non-GAAP adjusted EBITDA, a non-GAAP financial measure as defined below, was a loss $(2.0) million for the fourth quarter of 2016, compared with non-GAAP adjusted EBITDA loss of $(1.1) million for the fourth quarter of 2015. Non-GAAP Adjusted Net Income/Loss: Non-GAAP adjusted net loss, as defined below, for the fourth quarter of 2016 was $(3.2) million, or $(0.20) per share, compared with a non-GAAP adjusted net loss of $(2.2) million, or $(0.14) per share, for the fourth quarter of 2015. Cash and Cash Equivalents:  As of December 31, 2016, the Company had cash and cash equivalents of $8.6 million, compared with $15.3 million as of December 31, 2015. The Company used $1.6 million of cash from operating activities in the fourth quarter of 2016. Revenue:  Total revenue for fiscal year 2016 decreased 37% to $26.3 million from $41.6 million for fiscal year 2015, reflecting a 26% decrease in product revenue and a 42% decrease in service revenue. The decrease in the Company’s revenue in fiscal year 2016 was primarily driven by declining revenues related to the treatment of non-melanoma skin cancer in the United States. The decrease was also driven by a reduction of approximately $2.1 million of MRI-CAD product sales due to the Company’s exclusive distribution partner exercising its right in August 2015 to a fully paid-up license to distribute the software. This provided the Company with a cash payment of $2.0 million during the third quarter of 2015 that is being amortized over the term of the contract through July 2017.  Service revenue for fiscal year 2016 was approximately 60% of total revenues compared to approximately 66% of total revenues for fiscal year 2015. Cancer detection revenue for fiscal year 2016 decreased by 11%, which includes digital mammography, breast density, MRI and CT CAD platforms, as well as the associated service revenue.  When adjusted for the $2.1 million reduction in MRI-CAD product revenue, cancer detection revenues were essentially flat compared to fiscal year 2015.  Therapy revenue for fiscal year 2016 decreased by 59%, which includes Xoft® Axxent® Electronic Brachytherapy System® product sales, as well as the associated service revenue. Gross Profit:  Gross profit for fiscal year 2016 decreased to $18.5 million, or 70% of revenue, from $29.4 million, or 71% of revenue, for fiscal year 2015.  Gross profit for fiscal year 2016 included a U.S. medical device excise tax refund of $0.5 million. Operating Expenses:  Total operating expenses for fiscal year 2016 decreased to $28.5 million from $59.4 million for fiscal year 2015, which included $27.4 million of goodwill and long-lived asset impairment. Operating expenses for fiscal year 2015 were $32.0 million excluding the impairment.  The year-over-year decline reflects the effect of the Company’s cost reduction initiatives implemented in 2015. GAAP Net Loss:  Net loss for fiscal year 2016 was $(10.1) million, or $(0.63) per share, compared with net loss of $(32.5) million, or $(2.07) per share, for fiscal year 2015. Non-GAAP Adjusted EBITDA:  Non-GAAP adjusted EBITDA, a non-GAAP financial measure as defined below, was a loss of $(5.3) million for fiscal year 2016, compared with non-GAAP adjusted EBITDA of $3.9 million, or 9% of revenue, for fiscal year 2015. Non-GAAP Adjusted Net Income/Loss:  Non-GAAP adjusted net loss, as defined below, for fiscal year 2016 was $(9.8) million, or $(0.63) per share, compared with a non-GAAP adjusted net loss of $(2.2) million, or $(0.14) per share, for fiscal year 2015. iCAD management will host a conference call today at 4:30 p.m. Eastern Time to discuss the financial results and provide a company update.  The dial-in numbers are (855) 217-4501 for domestic callers and (716) 220-9431 for international callers.  The conference ID is 57732542.  A live webcast of the conference call will be available online at www.icadmed.com. A replay of the webcast will remain on the Company’s website until the Company releases its first quarter 2017 financial results.  In addition, a telephonic replay of the conference call will be available until March 15, 2017.  The replay dial-in numbers are (855) 859-2056 for domestic callers and (404) 537-3406 for international callers.  The replay conference ID is 57732542. Use of Non-GAAP Financial Measures In its quarterly news releases, conference calls, slide presentations or webcasts, the Company may use or discuss non-GAAP financial measures as defined by SEC Regulation G.  The GAAP financial measures most directly comparable to each non-GAAP financial measure used or discussed, and a reconciliation of the differences between each non-GAAP financial measure and the comparable GAAP financial measure, are included in this press release after the condensed consolidated financial statements.  When analyzing the Company's operating performance, investors should not consider these non-GAAP measures as a substitute for the comparable financial measures prepared in accordance with GAAP.  The Company's quarterly news releases containing such non-GAAP reconciliations can be found on the Investors section of the Company's website at www.icadmed.com. iCAD delivers innovative cancer detection and radiation therapy solutions and services that enable clinicians to find and treat cancers earlier and faster while improving patient outcomes.  iCAD offers a comprehensive range of upgradeable computer aided detection (CAD) and workflow solutions to support rapid and accurate detection of breast, prostate and colorectal cancers.  iCAD’s Xoft® Axxent® Electronic Brachytherapy (eBx®) System® is a painless, non-invasive technology that delivers high dose rate, low energy radiation, which targets cancer while minimizing exposure to surrounding healthy tissue.  The Xoft System is FDA cleared and CE marked for use anywhere in the body, including treatment of non-melanoma skin cancer, early-stage breast cancer and gynecological cancers.  The comprehensive iCAD technology platforms include advanced hardware and software, as well as management services designed to support cancer detection and radiation therapy treatments.  For more information, visit www.icadmed.com or www.xoftinc.com. "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995 Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.  Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.  Such factors include, but are not limited to the Company’s ability to defend itself in litigation matters, to achieve business and strategic objectives, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, uncertainty of future sales levels, protection of patents and other proprietary rights, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission.  The words “believe”, “demonstrate”, “intend”, “expect”, “would”, “could”, “consider”, “project”, “estimate”, “will”, “continue”, “anticipate”, “likely”, “seek”, and similar expressions identify forward-looking statements.  Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made.  The Company is under no obligation to provide any updates to any information contained in this release.  For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, including the 10-K for the year ended December 31, 2015, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov. RECONCILIATION OF NON-GAAP FINANCIAL MEASURES TO COMPARABLE GAAP MEASURES (Unaudited, in thousands, except per share amounts) The following is a reconciliation of the non-GAAP financial measures used by the Company to describe the Company's financial results determined in accordance with United States generally accepted accounting principles (GAAP).  An explanation of these measures is also included below under the heading "Explanation of Non-GAAP Financial Measures." While management believes that these non-GAAP financial measures provide useful supplemental information to investors regarding the underlying performance of the Company's business operations, investors are reminded to consider these non-GAAP financial measures in addition to, and not as a substitute for, financial performance measures prepared in accordance with GAAP.  In addition, it should be noted that these non-GAAP financial measures may be different from non-GAAP financial measures used by other companies, and management may utilize other measures to illustrate performance in the future.  Non-GAAP financial measures have limitations in that they do not reflect all of the amounts associated with the Company's results of operations as determined in accordance with GAAP. The Company reports its financial results in accordance with United States generally accepted accounting principles, or GAAP.  However, management believes that in order to properly understand the Company's short-term and long-term financial and operational trends, investors may wish to consider the impact of certain non-cash or non-recurring items, when used as a supplement to financial performance measures in accordance with GAAP.  These items result from facts and circumstances that vary in frequency and/or impact on continuing operations.  Management also uses results of operations before such items to evaluate the operating performance of the Company and compare it against past periods, make operating decisions, and serve as a basis for strategic planning.  These non-GAAP financial measures provide management with additional means to understand and evaluate the operating results and trends in the Company's ongoing business by eliminating certain non-cash expenses and other items that management believes might otherwise make comparisons of the Company's ongoing business with prior periods more difficult, obscure trends in ongoing operations or reduce management's ability to make useful forecasts.  Management believes that these non-GAAP financial measures provide additional means of evaluating period-over-period operating performance.  In addition, management understands that some investors and financial analysts find this information helpful in analyzing the Company's financial and operational performance and comparing this performance to its peers and competitors. Management defines "Non-GAAP Adjusted EBITDA" as the sum of GAAP net income (loss) before provision for taxes, acquisition-related expenses, total other (income) expense, stock-based compensation expense, depreciation and amortization, severance, gain on sale, loss on warrant, loss on extinguishment of debt, amortization of acquired intangibles, patent litigation and recall costs, contingent consideration, indemnification, asset and goodwill impairment charges.  Management considers this non-GAAP financial measure to be an important indicator of the Company's operational strength and performance of its business and a good measure of its historical operating trends, in particular the extent to which ongoing operations impact the Company's overall financial performance. Management defines "Non-GAAP Adjusted Net Income (loss)" as the sum of GAAP net income (loss) before provision for the gain on sale of asset, severance, transaction, patent litigation and recall costs, contingent consideration, indemnification, loss on extinguishment of debt and asset and goodwill impairment charges. Management considers this non-GAAP financial measure to be an important indicator of the Company's operational strength and performance of its business and a good measure of its historical operating trends, in particular the extent to which ongoing operations impact the Company's overall financial performance. Management excludes each of the items identified below from the applicable non-GAAP financial measure referenced above for the reasons set forth with respect to that excluded item: On occasion in the future, there may be other items, such as significant asset impairments, restructuring charges or significant gains or losses from contingencies that the Company may exclude if it believes that doing so is consistent with the goal of providing useful information to investors and management.

Loading CPT collaborators
Loading CPT collaborators